Comparison of structure-function correlation among IMO visual function analyser and Humphrey field analyser

Abstract

Purpose To compare the structure-function correlations between optical coherence tomography (OCT) thickness parameters and the corresponding sectorial mean sensitivity (MS) values obtained with IMO visual function analyser (IMOvifa) and Humphrey field analyser (HFA) perimeters. Design Prospective cross-sectional study. Methods Glaucoma suspect, glaucoma and ocular hypertension patients underwent IMOvifa 24-2 Ambient Interactive Zippy Estimated Sequential Testing, HFA 24-2 Swedish Interactive Threshold Algorithm-Standard and OCT tests within 12 weeks. Based on the Garway-Heath map, the sensitivity points were divided in corresponding OCT peripapillary retinal nerve fibre layer (pRNFL) sectors, and also the central 10° points in corresponding ganglion cell–inner plexiform layer thickness over the macula. The structure-function correlations were analysed by Spearman’s rank coefficient and compared by Steiger’s test. Results 57 eyes of 57 patients (mean age 59.2 years, 61.4% female) with reliable field and adequate OCT strength were included in this analysis. IMOvifa had significantly shorter testing time (3.7 vs 5.3 mins), lower mean deviation (difference −0.6 dB) and greater visual field index (difference +1.0%) compared with HFA (p<0.001 for all). There was moderate to strong correlation between IMOvifa and HFA MS sectors (p<0.001 for all). IMOvifa had significant correlations in the inferior (I, r=0.46), superior (S, r=0.45), temporal (T, r=0.28) pRNFL sectors and in the I (r=0.63) and S (r=0.53) mGCPIPL hemispheres (p≤0.03 for all). There was no significant difference in the strength of the correlation of IMOvifa versus HFA results with OCT parameters (p≥0.06). Conclusions The IMOvifa test took less time and resulted in slightly less severe defects than HFA. MS in all sectors was moderately to strongly correlated. Function-structure correlations were similar when using either perimeter. Data are available on reasonable request. For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing this request platform is Vivli: . For up to date details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: . Anonymised records for individual patients across more than one data source external to Roche can not, and should not, be linked due to a potential increase in risk of patient reidentification.